France Archives

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in one day… Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous […]

December 4, 2015 - 3 minutesmins - By Dani Bancroft

bioplastics carbios bioon france pet green

News and Trends 3 Dec 2015

Bioplastics Breakthrough: French Cleantech Now Able to Infinitely Recycle PETs!

French Carbios have now managed to adapt their enzymatic bioplastics manufacturing process to make Green PET (polyethylene terephthalate) from the petrochemical PET – one of the most common plastics. Whilst various green initiatives push for better regulation of recycling (a prime example being in Berlin!), in reality only around 10% of plastic collected is actually […]

December 3, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Dec 2015

Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

BIO-Europe 2015 was a good opportunity for us to meet people who are playing a key role in the Biotech industry. I had the opportunity to meet Miguel Sieler, CEO of Neovacs, a company that can potentially be the first to develop a therapeutic vaccine for lupus patients! Neovacs is a French biotechnology company developing […]

December 3, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 1 Dec 2015

Rare Diseases: Still a ‘Blue Ocean’ for Biotechs?

We all know the success stories linked to Rare Disease such as Genzyme. But I wanted to get a deeper understanding on what is today considered as Rare disease, who is acting the field and the reasons for so many Biotech companies to dive into the field. Last week was the RARE 2015 congress in […]

December 1, 2015 - 6 minutesmins - By Philip Hemme

lunar esa melissa terraforming ecosystem space

News and Trends 30 Nov 2015

Extra-Terrestrial Ecosystems: The European Space Agency MELiSSA Program

Researching how to bring sustainable life support systems from Earth to the moon or Mars is the first move by the European Space Agency in making Space livable on the longer term scale. Around 25 years ago the MELiSSA project was born…with the aim of easing human exploration of the Solar System, whilst also serving […]

November 30, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

regeneron sanofi praulant odyssey alirocumab cardiac statins

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]

November 19, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 19 Nov 2015

This 10,000 Employee French Pharma is Finally Entering the Biotech Partnership Race

Biotech is getting more and more about partnering rather than doing everything alone. Some conservative Pharmas, which worked to more of a ‘Silo model’, are now branching out in a more open approach; the last one being the Pharma company from the south-west of France Pierre Fabre. The company, named after its iconic founder Pierre Fabre, […]

November 19, 2015 - 3 minutesmins - By Philip Hemme

microbiome seres eligo flagship cancer evelo

News and Trends 17 Nov 2015

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

The Microbiome and Immuno-Oncology fields are hugely trendy in the Biotech Industry – and now a marriage between the two has finally occurred… The Microbiome field is still very new, with the launch of the US Human Microbiome Project just happening in 2008. Nonetheless, some start-ups are moving fast up the microbiome ranks, as well […]

November 17, 2015 - 3 minutesmins - By Dani Bancroft

genfit ceo mouney liver disease NASH elafibranor interview

News and Trends 16 Nov 2015

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the ‘Liver Meeting 2015‘ congress for the American Association for the study of Liver disease (AASLD) on Friday in San Francisco (US). Genfit is the European leader in NASH research (Non-alcoholic steatohepatitis), today making the news again at AASLD in San Francisco. The company, which […]

November 16, 2015 - 5 minutesmins - By Dani Bancroft

News and Trends 16 Nov 2015

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna…one of the biggest deals in Biotech today. Moderna is the mRNA therapies companies from Cambridge/Boston (US), most famous for having raised over 900 million dollars in VC money. I met Stephane one and a […]

November 16, 2015 - 1 minutemin - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us